Patent details
LUC50025 Product Name: Calquence - acalabrutinib
Basic Information
- Publication number:
- LUC50025
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP157570029
- Legal Status:
- Pending & Published
- Application number:
- LUC50025
- First applicant's nationality:
- Procedural language:
- English
Marketing Authorization
- Marketing Authorization Number:
- EU/1/20/1479
- Marketing Authorization Type:
- Marketing Authorization Date:
- 03/06/2025
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 28/11/2025
- First Marketing Authorization date:
- 03/06/2025
- Grant date:
- Activation date:
- Publication date:
- 28/11/2025
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 03/06/2040
- SPC Extension Expiration:
- 03/06/2040
- Rejection date:
- Withdrawal date:
Owner
- From:
- 28/11/2025
- Name:
- Acerta Pharma B.V.
- Address:
- Kloosterstraat 9, 5349 AB Oss, Netherlands (NL)
Agent
- Name:
- Patent42 SA
- From:
- 28/11/2025
- Address:
- 5, rue Dicks, 4081, Esch-sur-Alzette, Luxembourg (LU)
- To:
Publication
Bulletin
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2025/13
- Publication date:
- 04/12/2025
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
Annual Fees
- Annual Fee Due Date:
- 31/08/2035
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 28/11/2025 | Application Form | 5 |
| 28/11/2025 | Outgoing Correspondence | 2 |
| 28/11/2025 | General Document | 103 |
| 28/11/2025 | General Document | 3 |
| 28/11/2025 | General Document | 1 |
| 28/11/2025 | General Document | 1 |
| 28/11/2025 | Outgoing Correspondence | 1 |
| 28/11/2025 | Publication | 1 |